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Background: Ruxolitinib, a novel inhibitor of Janus kinases 1 and 2, was recently approved for the treatment of
myelofibrosis but, recently, attention has been drawn to potential side effects and especially opportunistic infections
and virus reactivations. EBV reactivation has not previously been reported to occur in association with Ruxolitinib.
Case presentation: We report a case of a 57 year old female with post-polycythemic myelofibrosis who was treated
with Ruxolitinib. Approximately 9 weeks later she presented with a rapidly fatal, suspected EBV driven lymphoproliferative
disorder in the CNS.
Conclusions: Our report further underlines that patients treated with Ruxolitinib should be monitored closely for
reactivations of opportunistic pathogens and viral infections.
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Ruxolitinib was recently approved for the treatment of mye-
lofibrosis and numerous studies are underway examining its
effect in other myeloproliferative neoplasms. This novel in-
hibitor of Janus kinases 1 and 2 has shown promising effects
in reducing constitutional symptoms and splenomegaly in
patients with myelofibrosis and more recently was also
shown to increase overall survival [1, 2]. Recently, attention
has been drawn to potential side effects of Ruxolitinib and
especially opportunistic infections and viral reactivations
[3–9]. Here we report on a patient with a rapidly fatal, sus-
pected EBV driven lymphoproliferative disorder in the CNS
developing shortly after administration of Ruxolitinb.Case presentation
A 57 year old Caucasian woman with a history of Polycy-
themia vera (PV) presented to our institution with pro-
gressive debilitating constitutional symptoms. She had
received her diagnosis 25 years ago and underwent splen-
ectomy 15 years earlier after a splenic vein thrombosis.
Three years earlier she was diagnosed with focal segmental
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cording to plasma Iohexol clearance of 43 mL/min/
1,73 m2 and a nephrotic syndrome. Earlier, her FSGS was
treated with Prednisolone, Tacrolimus and Adrenocortico-
trophic hormone (ACTH) but currently she was not under
active treatment. Throughout the years she received
numerous treatment modalities for her PV including phle-
botomy, 32P, Hydroxyurea and Anagrelide. At the time of
presentation progressive debilitating constitutional symp-
toms in the form of fatigue, low grade fever and weight
loss had developed. A diagnosis of post-polycythemic
myelofibrosis was made on a bone marrow biopsy. She
was treated with pegylated interferon alfa-2a but shortly
after her second injection developed severe headache that
required hospital admission. CT and MRI of the brain
were normal. Lumbar puncture was not performed. Pro-
gressive proteinuria was noted and the patient was treated
with Prednisolone 30 mg daily. The pegylated interferon
alfa 2a treatment was stopped and her headache gradually
disappeared. Three weeks later, treatment with Ruxolitinib
was started at a dose of 10 mg bid and the patient had a
partial resolution of symptoms. Approximately 9 weeks
after the beginning of Ruxolitinib therapy the patient was
admitted, now for three grand mal seizures.
On diffusion-weighted MRI scan of the brain there
was a 2 cm ring lesion in the right temporal lobe with
restricted diffusion and surrounding edema (Fig. 1). Thes article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Fig. 1 MRI of the head showing ring enhanced lesion in the right
temporal lobe with surrounding edema at the time of diagnosis
Fig. 2 MRI at time of progression 4 weeks later
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lymphoma. Retrospective examination of MRI taken
11 weeks earlier showed no signs of tumor. PET-CT
showed 18 F-FDG lesion uptake but no signs of dissemi-
nated disease. Cerebrospinal fluid (CSF) analysis showed
marginally elevated mononuclear cells (11 × 106/mL)
but flow cytometry analysis and cytology of the CSF
were negative. Bacterial and mycobacterial cultures were
negative. However, PCR analysis of CSF was positive for
Epstein-Barr virus with 100 000 copies/mL while only
mildly positive in serum with <250 copies/mL. PCR for
JC, CMV, HHV6, HSV and VZV virus in the CSF were
negative. A diagnosis of CNS lymphoproliferative dis-
order was suggested and Ruxolitinib was stopped. No
biopsy was made. Because of co-morbidities the patient
was deemed not to be a candidate for aggressive chemo-
therapy and palliative CNS radiotherapy, 24 Gy in 12
daily fractions, was commenced and she was treated
concurrently with Rituximab and Temozolamide. Her
condition worsened quickly thereafter and a repeated
MRI showed a progressive disease (Fig. 2), now with
multiple metastases in the brain and a midline shift. The
patient passed away 5 weeks after her diagnosis. An aut-
opsy was not performed.
Discussion
In the earlier studies on the efficacy and safety of Ruxoli-
tinib the major reported side effects were dose-relatedhematologic toxicity with anemia, neutropenia and throm-
bocytopenia. Herpes Zoster reactivation was described
and awareness for this is recommended as is screening
for latent tuberculosis [2]. Recently, published reports
have described viral reactivations of Hepatitis B [3, 5]
toxoplasma chorioretinitis [4], cryptococcus neoformans
[8], mucormycosis, herpes simplex [6] and pneumocystis
jiroveci [9] associated with the use of Ruxolitinib.
Studies have been conducted where the immunosup-
pressive effects of Ruxolitinib have been evaluated. A
phase 1/2 study showed a marked decrease in pro-
inflammatory cytokines in patients receiving Ruxolitinib
[10] which likely plays a role in the favorable effect of
the drug in reducing myelofibrosis related symptoms. A
pre-clinical model showed reduced dendritic cell func-
tion after the administration of Ruxolitinib resulting in
an impaired CD4+ and CD8+ T cell priming in vitro and
in vivo [11]. Another study in patients receiving Ruxoli-
tinib showed a marked and long-lasting decrease in
regulatory T-cells, which are known to have a protective
role against viral pathogens [12].
To our knowledge this is the first case describing EBV
driven suspected lymphoproliferative disorder during
Ruxolitinib therapy. Although no biopsy was made, the
radiographic finding of a cerebral ring enhanced lesion
with an avid 18 F-FDG uptake in a patient with a high
copy number of EBV in the CSF and the virtual absence
of EBV transcripts in serum, makes the suggested diag-
nosis highly plausible. Other differential diagnosis of
cerebral ring enhanced lesions including metastases,
abscesses or tuberculosis seem less likely in this case.
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munosuppressive factors such as asplenia and long term
steroid treatment, led to EBV reactivation in this patient
who was seropositive for EBV (IgG but not IgM) before
treatment initiation. The fact that the patient did undergo
an MRI of the brain, that was normal, only 3 weeks prior
to initiation of Ruxolitinib therapy strongly suggests that
the disorder developed after the beginning of Ruxolitinib
therapy.
Conclusions
We describe a patient with post-polycythemic myelofibro-
sis who was treated with Ruxolitinib. Nine weeks later she
presented with a rapidly fatal EBV driven suspected CNS
lymphoproliferative disorder which was refractory to
radiotherapy, Rituximab and Temozolamid. Our report
further underlines that patients treated with Ruxolitinib
should be monitored for reactivation of opportunistic
pathogens and viral infections, as recently suggested [13].
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